Champions Oncology, Inc. (CSBR) Q1 2027 earnings review
Radiopharm insourcing restores gross margin, but commercial spend consumes the leverage
Champions Oncology delivered 8.8% revenue growth to $15.2 million and expanded its oncology services margin by 800 basis points year-over-year to 51%. But an accompanying 66% jump in sales and marketing expense consumed the gross leverage entirely, leaving the GAAP operating loss essentially flat at $409,000. Cash balances fell another $500,000 to end the quarter at $4.3 million.
The print validated the central margin thesis: bringing radiopharmaceutical activities in-house successfully removed outsourced laboratory costs and reset the gross margin profile. However, the data-licensing narrative weakened; management cited increased data revenue but withheld the absolute figure, failing to publicly validate the Q4 claim that a delayed large agreement would materialise in Q1.
What remains open is whether the core business can generate enough cash to self-fund the Corellia therapeutics discovery arm. With cash dwindling and operating cash flow remaining negative, the timeline for spinning out or externally funding Corellia is the live question; the next quarter's cash-flow statement and any external funding announcements give the reading.
⚖️ Verdict: ⚪ Neutral
🐂 Bull Case
Radiopharmaceutical In-Housing Restores Gross Margin
The margin thesis played out exactly as management guided. By migrating radiolabeling work away from third-party labs and bringing those capabilities in-house, Champions expanded its oncology services margin to 51%, up 8 points from the 43% recorded a year ago. That 43% print was the weakest of the trailing four-quarter window; clearing it comfortably confirms the cost base reset.
With the temporary outsourced costs now largely flushed from cost of revenue, the 51% reading sits firmly inside management's stated target range for the core business.
Core Services Conversion Holds Up the Top Line
Revenue grew 8.8% year-over-year to $15.2 million and 10.1% sequentially, driven largely by better study execution and contract conversion in the core research services business. Last quarter, the delayed conversion of backlog dragged down the forward book; this print shows operations moving that contracted work steadily through the revenue line.
🐻 Bear Case
Commercial Expansion Consumes the Margin Leverage
The narrative has been that gross margin restoration would drop directly to the bottom line, but the company spent the entire gain on commercial expansion. Sales and marketing expense increased 66.6% to $3.1 million, expanding from 13.2% of revenue a year ago to 20.2% this quarter. Management attributed the jump to hiring within the commercial organization for both research services and data licensing.
Because S&M grew +7.0 points against revenue while gross margin improved +8.0 points, operating leverage was neutralised. The GAAP operating loss narrowed only slightly to $409,000, and the cash drain continues unabated.
Liquidity and the Corellia Drag
Cash fell another 10% sequentially to $4.3 million, down from $10.3 million a year ago. Operating cash flow remains negative at -$492,000 for the quarter, and the company has no reported debt facility to draw on.
The drag comes primarily from self-funding the Corellia target discovery unit. Research and development expense rose 12.6% year-over-year to $2.3 million, which management explicitly tied to Corellia share-based compensation. With negative working capital and cash continuing to bleed, the timeline for securing external funding for Corellia is tightening before a capital raise becomes unavoidable.
Standing risks the print did not read on
Three standing risks drawn from the fiscal 2026 year-end print were not resolved in this quarter's release:
- Data licensing viability: Management claimed in Q4 that a delayed large agreement would materialise in Q1; the release notes 'increased data license revenue' but withholds the dollar amount entirely.
- Customer concentration: The 10-K showed one customer representing 24% of revenue; the Q1 release offers no update on customer diversification.
- Forward book: Deferred revenue remains down 33.8% from a year ago, keeping the risk alive that the revenue base could contract if new bookings do not accelerate.
💲 Other KPIs
Net new deferred revenue turned positive at +$0.7 million for the quarter, breaking a four-quarter streak of sequential declines. However, the balance remains down 33.8% against the $14.4 million recorded a year ago.
Accelerated from $59,000 a year ago and $158,000 in Q4, validating management's claim that core operations are scaling. The metric adds back $766,000 of stock-based compensation, which shields the cash bleed from the profitability headline.
Grew 12.6% year-over-year, consuming 15.4% of revenue. The increase primarily reflects share-based compensation tied to the Corellia subsidiary, keeping pressure on the operating line.
❓ Key Questions
Data Licensing Conversion
What was the exact dollar contribution of data license revenue in Q1, and did it include the specific large agreement that slipped out of Q4?
Commercial Expense Baseline
Does the 66% year-over-year increase in sales and marketing represent the new quarterly baseline required to support the data platform, or were there one-time commercial expansion costs incurred this quarter?
Corellia Funding Timeline
With cash down to $4.3 million and operating cash flow remaining negative, at what cash threshold does self-funding the Corellia entity cease if an external funding round is not closed?
Customer Concentration
What is the current revenue concentration of the top account that accounted for 24% of total revenue at year-end?